Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity

Inclusion Criteria: * Patients must have histologically confirmed relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from of follicular lymphoma * Age ≥ 18 years * ECOG or Karnofsky performance status of ≤ 2 * Patients must have a caregiver(s) with them 24 hours a day for the first 30 days after CAR-T cell infusion * Patients must stay within a 30-minute distance from the cancer center * Patients must have access to wifi network or a cellular network * Patients and caregiver(s) participating in patient's care must attend the education session for outpatient CAR-T and demonstrate competency to collect vital signs with equipment provided * Must have the ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative). Exclusion Criteria: * Patients who have acute lymphoblastic leukemia/lymphoma * Patients who have a high tumor burden (\> 10 cm largest mass) have a high risk of CRS who will receive CAR-T as an inpatient * Patient or caregiver unable to understand and follow English language * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.